Janus Kinase (JAK) Inhibitors – Key Insights Into the Evolving Competitive Landscape and Key Companies Engaged in the Market

November 23 23:04 2022
Janus Kinase (JAK) Inhibitors - Key Insights Into the Evolving Competitive Landscape and Key Companies Engaged in the Market
Delveinsight Business Research LLP

As per DelveInsight’s assessment, globally, about 40+ companies are working on 45+ drugs in the Janus kinase (JAK) Inhibitors Market.

Janus kinase (JAK) inhibitors Competitive landscape, 2022” report by DelveInsight outlines a comprehensive assessment of the present clinical/non-clinical development activities and growth prospects across the  Janus Kinase (JAK) Inhibitors Market. 

The Janus Kinase (JAK) Inhibitors Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. 

The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.

Janus Kinase (JAK) Inhibitors Pipeline Analysis

The report provides insights into: 

  • The report provides detailed insights about Janus Kinase (JAK) Inhibitors and the aggregate therapies developed by major pharma companies.

  • It accesses the different Janus Kinase (JAK) Inhibitors therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development.

  • It outlines the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

  • The report evaluates the drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 

  • It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the Janus Kinase (JAK) Inhibitors market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.  

Learn How the Ongoing Clinical & Commercial Activities will Affect the Janus Kinase (JAK) Inhibitors Therapeutic Segment:

https://www.delveinsight.com/sample-request/janus-kinase-jak-inhibitors-competitive-landscape

Janus Kinase (JAK) Inhibitors Therapeutics Landscape

Janus kinase (JAK) inhibitors are small molecules of approximately 400 Da that could be administrated as oral medicines. JAKs are phosphotransferases that bind to the intracellular domains of cytokine receptors and transmit signals to activate immune responses. Currently, several clinical trials with several JAK inhibitors are ongoing, from cancer, such as myelofibrosis, to autoimmune diseases, such as psoriasis. In the future, it is possible that JAK inhibitors also be effective in multiple disorders therapy.

Some of the key companies in the Janus kinase (JAK) Inhibitors Market include

  • Pfizer

  • Sierra Oncology

  • Theravance Biopharma

  • Dizal Pharmaceutical

  • Aclaris Therapeutics

  • Celon Pharma

  • Incyte Corporation

  • AbbVie

  • Galapagos

  • Gilead Sciences

  • Reistone Biopharma

  • Jiangsu Hengrui Medicine Co.

And many others

The Janus kinase (JAK) Inhibitors Products covered in the report include:

  • RINVOQ (AbbVie)

  • Filgotinib (Galapagos)

  • TD-8236 (Theravance Biopharma)

And many more

Request the Sample PDF to Get a Better Understanding of the Emerging Drugs and Key Companies:

https://www.delveinsight.com/sample-request/janus-kinase-jak-inhibitors-competitive-landscape

Table of Content (TOC)

1. Report Introduction

2. Executive Summary

3. Janus Kinase (JAK) Inhibitors Current Treatment Patterns

4. Janus Kinase (JAK) Inhibitors – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Janus Kinase (JAK) Inhibitors Late Stage Products (Phase-III)

7. Janus Kinase (JAK) Inhibitors Mid-Stage Products (Phase-II)

8. Janus Kinase (JAK) Inhibitors Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Janus Kinase (JAK) Inhibitors Discontinued Products

13. Janus Kinase (JAK) Inhibitors Product Profiles

14. Key Companies in the Janus Kinase (JAK) Inhibitors Market

15. Key Products in the Janus Kinase (JAK) Inhibitors Therapeutics Segment

16. Dormant and Discontinued Products

17. Janus Kinase (JAK) Inhibitors Unmet Needs

18. Janus Kinase (JAK) Inhibitors Future Perspectives

19. Janus Kinase (JAK) Inhibitors Analyst Review  

20. Appendix

21. Report Methodology

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF to Explore the Key Offerings of the Report @

https://www.delveinsight.com/sample-request/janus-kinase-jak-inhibitors-competitive-landscape

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

  Categories: